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SUMMARY
Background
Performance of non-invasive ﬁbrosis biomarkers may be inﬂuenced by aeti-
ology of chronic liver disease (CLD) and the stages of hepatic ﬁbrosis, but
large-scale studies are pending.
Aim
To investigate the effect of aetiogy and stages of hepatic ﬁbrosis on the per-
formance of ﬁbrosis biomarkers.
Methods
A total of 2411 patients with compensated CLD (HCV = 75.1%,
HBV = 10.5%, NASH = 7.9%, HIV ⁄HCV = 6.5%) were consecutively
enrolled in 9 centres. APRI, Forns’index, Lok index, AST-to-ALT ratio,
Fib-4, platelets and Fibrotest-Fibrosure were tested against liver biopsy,
considered the gold standard. The effect of the stages of hepatic ﬁbrosis to
diagnose signiﬁcant ﬁbrosis and cirrhosis (‡F2 and F4 respectively) was
investigated through difference between advanced and non-advanced ﬁbro-
sis stages (DANA). Performance was expressed as observed area under the
ROC curve (ObAUROC) and AUROC adjusted for DANA (AdjAUROC).
Results
Performance of APRI and Fibrotest-Fibrosure was higher than other bio-
markers. In all aetiologies, AdjAUROC was higher than ObAUROC. APRI
showed its best performance in HCV monoinfected cases, with an AdjAU-
ROC of 0.77 and 0.83 for ‡F2 and F4 respectively. In HBV and non-alco-
holic steatohepatitis (NASH) patients, its performance was poor
(AdjAUROC <0.70). Performance of Fibrotest-Fibrosure was good in all
aetiologies for both ‡F2 and F4 (AdjAUROC >0.73), except for ‡F2 in
NASH (AdjAUROC = 0.64). Performance of all biomarkers was reduced in
HCV cases with normal ALT.
Conclusions
Aetiology is a major factor inﬂuencing the performance of liver ﬁbrosis bio-
markers. Even after correction for DANA, APRI and Fibrotest-Fibrosure
exhibit the best performance. However, liver biopsy is not replaceable, espe-
cially to diagnose ‡F2 and in HCV carriers with normal ALT.
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INTRODUCTION
Chronic infection with the hepatitis B (HBV) and C
(HCV) viruses and non-alcoholic steatohepatitis (NASH)
are the main causes of chronic and progressive liver dis-
ease worldwide, leading to cirrhosis, end-stage liver dis-
ease and hepatocellular carcinoma (HCC).1–3 Moreover,
due to common routes of transmission, up to one-third
of patients infected with the human immunodeﬁciency
virus (HIV) in the US and Europe are coinfected with
HCV or HBV.4, 5 These different aetiological forms of
chronic liver disease (CLD) share a common histopath-
ological pathway that is the formation and accumulation
of ﬁbrosis, which leads to progressive distortion of the
hepatic architecture, that is the hallmark of evolution to
cirrhosis.6 Natural history studies indicate that advanced
ﬁbrosis and cirrhosis develop in about 20–40% of
patients with chronic hepatitis B (CHB) or chronic hep-
atitis C (CHC) and in a similar proportion of those
with NASH.7–9 Staging of liver ﬁbrosis by liver biopsy
represents the gold standard for prognostic assessment
and, in CHC and CHB, for deciding to initiate anti-viral
therapy.10 Liver biopsy, however, has a number of limi-
tations, being invasive, costly, difﬁcult to standardise
and disliked by many patients.11–13 Its universal use in
CLDs is unpractical due to the huge number of patients
who are often asymptomatic.2, 14 Recently, increasing
interest has been directed towards the use of non-inva-
sive tools to assess liver ﬁbrosis. These include simple
markers based on routinary tests, like platelets, AST-to-
platelet ratio index (APRI), Forns’ index, Fib-4, Lok
index and AST-to-ALT ratio (AAR), and other more
sophisticated and patented tests, such as Fibrotest-Fibro-
sure.15–21 In the midst of a large series of publications
on these markers, investigated mainly in CHC, their
implementation in clinical practice is still debated and
large-scale studies in aetiological forms other than HCV
are still limited.12, 13, 22 Recently, it has been shown that
the performance of these biomarkers may be inﬂuenced
by the prevalence of liver ﬁbrosis stages deﬁning
advanced and non-advanced ﬁbrosis in the analysed
patients cohort.23, 24 Poynard and colleagues have there-
fore concluded that area under the receiving operating
characteristic curve (AUROC), that is generally used to
describe performance, should be standardised accord-
ingly.23 The aim of this large-scale, international, inde-
pendent study was to investigate the effect of aetiology
of liver disease and of the stages of hepatic ﬁbrosis on
the performance of several non-invasive biomarkers in
patients with CLD.
METHODS
Study design
This was an International, multicentre retrospective
study conducted in nine clinical centres across Europe.
Patients with CLDs of any aetiology were enrolled,
according to inclusion and exclusion criteria. Our aim
was to investigate the effect of liver disease aetiology and
the stages of hepatic ﬁbrosis on the performance of a
series of non-invasive biomarkers for liver ﬁbrosis.
Details of patients’ demographics, aetiology of CLDs, lab-
oratory results and liver biopsy were recorded in each
Centre. The study was conducted according to the Decla-
ration of Helsinki.
Inclusion and exclusion criteria
We included consecutive patients admitted between
January 2003 and December 2008. The inclusion crite-
ria were (i) a diagnosis of well-compensated CLD of
any aetiology and (ii) availability of both liver biopsy
and relevant parameters for the assessment of non-
invasive biomarkers, performed on the same day.
Exclusion criteria were (i) decompensated liver cirrho-
sis; (ii) comorbidities that could confound the interpre-
tation of non-invasive biomarkers, including
haemolysis, Gilbert’s syndrome, thrombocytopenia not
liver-related; (iii) history or evidence at entry of HCC;
(iv) liver transplantation. All patients gave their
informed consent to be included in the study. Out of
2805 consecutive patients with CLDs who had a liver
biopsy and non-invasive biomarkers performed on the
same day, we included 2411 patients. A total of 221
were excluded for decompensated liver cirrhosis, 56 for
confounding factors for the non-invasive biomarkers,
105 for HCC and 14 for previous liver transplantation.
Patients with chronic viral hepatitis were treatment-
naı¨ve.
Aetiologies of liver disease
HCV infection was established by a positive third-genera-
tion anti-HCV test (Ortho Diagnostic Systems, Raritan,
NJ, USA), with serum HCV-RNA detected by polymerase
chain reaction (PCR) (Amplicor HCV Monitor test, Roche
Diagnostics, Indianapolis, IN, USA). The HCV genotype
was determined by INNOLipa (Innogenetics, Bayer,
Ghent, Belgium). Diagnosis of HBV infection was based
on the presence of HBsAg for more than 6 months, and
HBeAg ⁄ anti-HBe were determined using commercial
assays (Roche Diagnostics, Basel, Switzerland). HBV-DNA
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level was measured by real-time PCR. HIV infection was
deﬁned by HIV ELISA, conﬁrmed by Western blot assay,
with positive HIV-RNA. The diagnosis of NASH was
based on liver histology. Secondary causes of steato-
hepatitis including signiﬁcant alcohol consumption
(‡100 g ⁄week) and the use of hepatotoxic drugs were
excluded. Among patients with either HCV or HBV infec-
tion, 487 (20.2%) subjects admitted occasional alcohol
consumption and 29 (1.2%), moderate alcohol consump-
tion.
Histological assessment
Liver biopsies were analysed in each centre by the
local pathologist who was unaware of clinical data.
Diagnosis of NASH was based on the common fea-
tures including steatosis, inﬂammation (portal and lob-
ular), hepatocyte ballooning and ﬁbrosis, according to
the scoring system recently developed by the NIH-
sponsored NASH Clinical Research Network.25 In
patients with CHC, or CHB or HIV ⁄HCV coinfection,
ﬁbrosis was scored according to METAVIR classiﬁca-
tion as follows: F0, no ﬁbrosis; F1, portal ﬁbrosis
without septa; F2, portal ﬁbrosis with few septa; F3,
numerous septa without cirrhosis; and F4, cirrhosis.26–29
Staging of liver ﬁbrosis in NASH patients was as fol-
lows: F0, normal connective tissue; F1, foci of
perivenular or pericellular ﬁbrosis in zone 3; F2, pe-
rivenular or pericellular ﬁbrosis conﬁned to zones 3
and 2, with or without portal ⁄periportal ﬁbrosis; F3,
bridging or septal ﬁbrosis; and F4, cirrhosis.30
Non-invasive biomarkers for liver fibrosis
The following non-invasive biomarkers were determined
in all patients, according to published formulas: platelets,
AAR, APRI, Forns’ index, Lok index, Fib-4. Fibrotest-
Fibrosure values were obtained through Biopredictive
(Biopredictive, Paris, France) or by courtesy of Prof. Thi-
erry Poynard. For all non-invasive biomarkers investi-
gated, the cut-off values indicated in the original reports
or in subsequent studies in various aetiologies of CLD
were applied.15–21, 27, 31–33
Outcome measures
Performance of non-invasive biomarkers was assessed for
the detection of: (i) signiﬁcant ﬁbrosis (‡F2 according to
METAVIR or NASH classiﬁcation) and (ii) cirrhosis
(F4) as these threshold are generally considered clinically
relevant to initiate anti-viral therapy and for speciﬁc
management and follow-up protocols.34–37
Statistical analysis
Descriptive results were expressed as mean  s.d. (stan-
dard deviation) or number (percentage) of patients with a
condition. The t-test or non parametric Mann–Whitney
test was used to compare quantitative data and the chi-
squared test was applied for comparison of frequency data.
All tests were two-tailed and P-values <0.05 were consid-
ered signiﬁcant. The performance of the non-invasive
methods for liver ﬁbrosis was measured as sensitivity,
speciﬁcity, positive and negative predictive value (PPV and
NPV respectively), accuracy, positive and negative likeli-
hood ratio (LR). Sensitivity, speciﬁcity, PPV, NPV and
accuracy were expressed as percentage. The diagnostic
value of the non-invasive biomarkers was expressed and
compared using the AUROC and its corresponding 95%
conﬁdence intervals (CI). AUROCs were calculated includ-
ing non-invasive markers’ quantitative values using empir-
ical non parametric method according to DeLong et al.
and compared using the method of Hanley et al.38, 39
Standardisation of AUROCs according to the
prevalence of fibrosis stages
As recently proposed by Poynard et al., AUROCs were
adjusted according to the prevalence of ﬁbrosis stages
using the DANA (Difference between advanced and non-
advanced ﬁbrosis).23 The DANA is an index for standar-
dising comparisons to transform any different prevalence
proﬁle into a homogeneous distribution of ﬁbrosis stages
from F0 to F4, as deﬁned by a prevalence of 0.20 for each
of the ﬁve METAVIR stages (standard prevalence).
DANA was calculated according to the following formula:
[(prevalence F2 · 2 + prevalence F3 · 3 + prevalence F4
· 4) ⁄ (prevalence F2 + prevalence F3 + prevalence F4)] –
[prevalence F1 ⁄ (prevalence F0 + prevalence F1)]. The
adjusted AUROCs (adjAUROCs) were calculated as fol-
lows: AdjAUROC = observed AUROC (obAUROC) +
(0.1056) · (2.5 – DANA).
RESULTS
Demographics, laboratory and histological features of
the 2411 patients with CLDs
Overall, there were 1391 males and 1020 females with
mean age of 46.9  12.1 years. Of 1968 patients with
CHC, either monoinfected or HIV coinfected, 1381
(70.2%) were infected with genotype 1 of HCV. Of 253
patients with CHB, 13 (5.1%) were coinfected with HDV
and 46 (18.2%) were HBeAg positive. The main demo-
graphic, laboratory and histological features, and their
G. Sebastiani et al.
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distribution by aetiological subgroups are summarised in
Table 1. Overall, 1112 (46.1%) patients had signiﬁcant
ﬁbrosis and 239 (9.9%) had cirrhosis. The mean length of
liver specimen was 17.7  8.4 mm and the mean number
of portal tracts was 10.6  5.9. Biopsy length was greater
than 15 mm in 1466 (60.8%) and greater than 20 mm in
1027 (42.6%) patients. As compared with the whole popu-
lation, patients with CHB and those with HIV ⁄HCV
coinfection were younger (P = 0.01 and P = 0.004 respec-
tively), whereas patients with NASH were signiﬁcantly
older (P = 0.001). Male gender was more frequent in CHB
and HIV ⁄HCV coinfected patients and in cases with
NASH (P < 0.0001, P = 0.001 and P < 0.0001 respec-
tively). As expected, patients with NASH had a signiﬁ-
cantly higher BMI when compared with the whole
population of the study (P < 0.0001). Platelets were signiﬁ-
cantly lower in patients with CHB and HIV ⁄HCV coinfec-
tion with respect to the whole population (P = 0.006 and
P = 0.01 respectively). Moreover, AST levels were signiﬁ-
cantly higher in patients with NASH and HIV ⁄HCV coin-
fection as compared with the whole population (P = 0.01
and P = 0.004 respectively). The distribution of liver ﬁbro-
sis stages also showed some signiﬁcant differences: patients
with CHB had more advanced ﬁbrosis stages, and patients
with HIV ⁄HCV coinfection had less advanced ﬁbrosis
stages when compared with the whole population (signiﬁ-
cant ﬁbrosis being present in 57.7% and 33.5% of cases vs.
46.1%; P = 0.0004 and P = 0.002 respectively).
Effect of the stages of hepatic fibrosis on the
performance of non-invasive biomarkers to diagnose
significant fibrosis
The performance of non-invasive biomarkers to diagnose
signiﬁcant ﬁbrosis and the effect of the stages of hepatic
ﬁbrosis are shown in Table 2. Overall, among the non-
invasive biomarkers considered, Fibrotest-Fibrosure and
APRI showed the best performance. For all non-invasive
biomarkers, the correction of the ObAUROC for DANA
resulted in a higher AdjAUROC, although this difference
was not statistically signiﬁcant. Fibrotest-Fibrosure was
able to classify 100% of cases, a ﬁgure that was signiﬁ-
cantly higher than that of APRI, Forns’ index and Fib-4
(P < 0.0001). Even when corrected for DANA, Fibrotest-
Fibrosure and APRI showed the best performance for
signiﬁcant ﬁbrosis, as indicated by an AdjAUROC of
0.76 and of 0.74 respectively.
Effect of the stages of hepatic fibrosis on the
performance of non-invasive biomarkers to diagnose
cirrhosis
The performance of non-invasive biomarkers to diag-
nose cirrhosis and the effect of the stages of hepatic
Table 2 | Performance of non-invasive biomarkers for significant fibrosis and correction for the stages of hepatic
fibrosis in 2411 patients with CLDs
APRI Forns’ index Fib-4
Fibrotest-
Fibrosure
Cut-off 0.5 1.5 4.2 6.9 1.45 3.25 0.49
Classified cases (%) 67.5 56.9 60.0 100
Sensitivity (%) 67.9 37.4 76.0 65.6 70.5 55.0 61.0
Specificity (%) 71 95.9 60.0 50.8 65.0 60.0 83.0
PPV (%) 66.7 85.1 77.2 72.1 73.4 66.2 79.2
NPV (%) 72 60.6 59.3 70.4 60.1 40.5 62.4
Accuracy (%) 64.3 69.5 68.5 70.9 67.3 72.0 71.3
LR+ 2.34 9.12 1.9 1.33 2.01 1.63 3.59
LR) 0.45 0.65 0.4 0.68 0.45 0.58 0.47
DANA 1.90
ObAUROC (95% CI)
0.68 (0.62–0.74) 0.67 (0.61–0.73) 0.66 (0.61–0.71)
0.7 (0.65–0.75)
AdjAUROC (95% CI) 0.74 (0.68–0.80) 0.73 (0.67–0.79) 0.72 (0.67–0.77) 0.76 (0.71–0.81)
AdjAUROC, adjusted area under the curve; APRI, AST-to-platelet ratio index; CI, confidence interval; DANA, difference between
advanced and non-advanced fibrosis; LR, likelihood ratio; NPV, negative predictive value; ObAUROC, observed area under the
curve; PPV, positive predictive value.
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ﬁbrosis are shown in Table 3. Overall, among the non-
invasive biomarkers considered, APRI and Fibrotest-
Fibrosure showed the best performance for cirrhosis.
The performance of AAR was rather poor and signiﬁ-
cantly lower than that of platelets, APRI and Fibrotest-
Fibrosure (P < 0.0001). APRI and Lok index were able
to classify less number of cases than Fibrotest-Fibrosure,
AAR and platelets (86.7% and 52.3% vs. 100% respec-
tively, P < 0.0001) For all non-invasive biomarkers, the
correction of the ObAUROC for DANA resulted in a
higher AdjAUROC, although this difference was not sta-
tistically signiﬁcant. Even when corrected for DANA,
APRI and Fibrotest-Fibrosure showed the best perfor-
mance for cirrhosis, as indicated by an AdjAUROC of
0.80 and of 0.79 respectively. Interestingly, both APRI
and Fibrotest-Fibrosure showed a high NPV (>93%) to
exclude cirrhosis.
Impact of aetiology of liver diseases on the
performance of non-invasive biomarkers
A subgroup analysis according to different aetiologies was
performed for the non-invasive biomarkers and their
respective cut-off values that showed the best performance
in the whole series of patients. APRI showed its best per-
formance in CHC, with an AdjAUROC of 0.77 for signiﬁ-
cant ﬁbrosis and an AdjAUROC of 0.83 for cirrhosis
(Table 4). Although slightly inferior, the performance of
APRI in HIV ⁄HCV coinfected patients was not signiﬁ-
cantly different from that in monoinfected HCV cases,
with an AdjAUROC of 0.74 for signiﬁcant ﬁbrosis and an
AdjAUROC of 0.77 for cirrhosis. In CHB, APRI showed a
signiﬁcantly lower performance than in CHC, with an
AdjAUROC of 0.69 for signiﬁcant ﬁbrosis and an AdjAU-
ROC of 0.66 for cirrhosis (P < 0.0001). The performance
of APRI was signiﬁcantly lower for NASH vs. CHC for
both signiﬁcant ﬁbrosis and cirrhosis (P < 0.0001). Inter-
estingly, APRI showed a high NPV (>97%) to exclude
presence of cirrhosis in both HCV monoinfected and
HIV ⁄HCV coinfected cases.
Fibrotest-Fibrosure showed its best performance in
CHC, with an AdjAUROC of 0.77 for signiﬁcant ﬁbrosis
and 0.79 for cirrhosis (Table 5). The performance of
Fibrotest-Fibrosure in HIV ⁄HCV coinfected patients was
similar to that in HCV monoinfected cases. In CHB,
Fibrotest-Fibrosure showed a slightly reduced perfor-
mance than in CHC for diagnosis of cirrhosis, but this
difference was not signiﬁcant. Conversely, performance
of Fibrotest-Fibrosure for signiﬁcant ﬁbrosis was signiﬁ-
cantly lower for NASH vs. CHC (P < 0.0001). On the
other hand, the performance of Fibrotest-Fibrosure for
cirrhosis was signiﬁcantly higher in NASH cases vs.
HBV cases (P < 0.0001). Interestingly, in all aetiologies
except for CHB, Fibrotest-Fibrosure showed a very high
NPV (>95%) to exclude presence of cirrhosis.
Table 3 | Performance of non-invasive biomarkers for cirrhosis and correction for the stages of hepatic fibrosis in 2411
patients with CLDs
Platelets APRI Lok index AAR Fibrotest-Fibrosure
Cut-off 150 1 2 0.2 0.5 1 0.75
Classified cases (%) 100 86.7 52.3 100 100
Sensitivity (%) 53.3 74.0 41.3 76.0 56.5 43.4 54.1
Specificity (%) 85.7 82.6 93.7 40.0 60.7 58.3 90.1
PPV (%) 34.6 31.7 41.8 30.5 66.0 66.7 60.8
NPV (%) 92.9 96.7 93.6 88.5 40.3 35 93.8
Accuracy (%) 77.9 81.7 88.5 66.8 69.7 48.6 86.3
LR+ 3.72 4.25 6.56 1.27 1.44 1.04 5.46
LR) 0.54 0.31 0.63 0.6 0.71 0.97 0.51
DANA 1.90
ObAUROC (95% CI) 0.72 (0.66–0.78) 0.74 (0.69–0.79) 0.63 (0.57–0.69) 0.54 (0.48–0.60) 0.73 (0.68–0.78)
AdjAUROC (95% CI) 0.78 (0.72–0.84) 0.80 (0.75–0.85) 0.69 (0.63–0.75) 0.6 (0.54–0.66) 0.79 (0.74–0.84)
AdjAUROC, adjusted area under the curve; APRI, AST-to-platelet ratio index; CI, confidence interval; DANA, difference between
advanced and non-advanced fibrosis; LR, likelihood ratio; NPV, negative predictive value; ObAUROC, observed area under the
curve; PPV, positive predictive value.
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Effect of other variables on the performance of
non-invasive biomarkers
The inﬂuence of other variables on the performance of
the non-invasive biomarkers, which exhibited the best
performance, was also investigated. Inter-centre variabil-
ity was marginal (data not shown). The effect of liver
biopsy size on the performance of non-invasive biomar-
kers was also studied. As regards APRI, similar perfor-
mance was observed for subjects with biopsy samples
<20 mm as compared with those with specimens
>20 mm: AdjAUROC = 0.72 (0.66–0.78, 95% CI) vs.
0.75 (0.70–0.80, 95% CI) for signiﬁcant ﬁbrosis, and 0.79
(0.75–0.83, 95% CI) vs. 0.80 (0.75–0.85, 95% CI) for cir-
rhosis respectively. On the same line, as regards Fibro-
test-Fibrosure, similar performance was observed for
subjects with biopsy samples <20 mm as compared with
those with specimens >20 mm: AdjAUROC = 0.74
(0.68–0.80, 95% CI) vs. 0.76 (0.71–0.81, 95% CI) for sig-
niﬁcant ﬁbrosis, and 0.79 (0.75–0.83, 95% CI) vs. 0.79
(0.74–0.84, 95% CI) for cirrhosis respectively.
Performance of non-invasive biomarkers in HCVpatients
with normal ALTand in elderly patients with CHC
To assess the performance of non-invasive biomarkers
and the effect of DANA in patients who may have a
peculiar distribution of liver ﬁbrosis stages, a dedicated
analysis was conducted on two subgroups of patients: (i)
HCV patients with normal ALT, who are expected to
have a lower prevalence of advanced ﬁbrosis stages; (ii)
HCV elderly patients (age ‡65 years), who are expected
to have a higher prevalence of advanced ﬁbrosis stages.
Indeed, these two subgroups of patients represent the
vast majority of HCV carriers in the general population
in most Western Countries, with an indication to liver
biopsy that is often debated and controversial.40–42
Overall, 595 (32.9%) HCV cases had normal ALT and
190 (10.5%) cases were over 65 years of age. The main
demographic, laboratory and histological features of the
two subgroups and comparison with the whole popula-
tion study are summarised in Table S1. When compared
with the whole study population, patients with normal
ALT were signiﬁcantly younger (P = 0.001) and had a
lower prevalence of advanced ﬁbrosis stages (signiﬁcant
ﬁbrosis being present in 29.5% vs. 45.3%, P < 0.0001).
Moreover, they present with lower frequency of male
gender (P < 0.0001) and higher platelets (P < 0.0001)
with respect to the whole population.
Overall, performance of all non-invasive biomarkers
for signiﬁcant ﬁbrosis in patients with normal ALT was
rather poor, with ObAUROC <0.65 for all the non-inva-
sive markers tested (Table S2). When correction for
DANA was applied, APRI and Fibrotest-Fibrosure
showed the highest performance, which remained, how-
ever, only discrete (AdjAUROC of 0.71 for APRI and
0.70 for Fibrotest-Fibrosure). These ﬁgures were lower
than those observed in the whole population, even if the
difference was not statistically signiﬁcant. On the same
line, performance of all non-invasive biomarkers for cir-
rhosis was lower than in the whole population, the high-
est ObAUROC being 0.65 (Table S3). The performance
of AAR was signiﬁcantly lower than that of platelets,
APRI and Fibrotest-Fibrosure (P < 0.0001). When cor-
rection for DANA was applied, APRI and Fibrotest-Fi-
brosure showed the highest performance, with an
AdjAUROC of 0.73 for both markers.
As regards elderly patients with HCV, they had a signif-
icantly lower prevalence of male gender (P < 0.0001),
higher BMI (P = 0.04), lower platelets (P = 0.005) and
higher AST and ALT (P = 0.01 and P < 0.0001 respec-
tively) (Table S1). As expected, elderly HCV patients pres-
ent with a higher prevalence of advanced ﬁbrosis stages
(signiﬁcant ﬁbrosis being present in 71.0% vs. 45.3%,
P < 0.0001) when compared with the whole population.
Overall, performance of all non-invasive biomarkers
for signiﬁcant ﬁbrosis in HCV elderly patients was similar
to that of the whole population (Table S4). Among the
non-invasive biomarkers considered, Fibrotest-Fibrosure
and APRI showed the best performance for diagnosis of
signiﬁcant ﬁbrosis, as indicated by an AdjAUROC of 0.74
for both markers. As regards the diagnosis of cirrhosis,
platelets showed the best performance, as indicated by an
AdjAUROC of 0.87. Interestingly, platelets showed the
highest NPV (>95%) to exclude cirrhosis (Table S5).
DISCUSSION
The results of this large-scale, multicentre, independent
study showed that aetiology of CLDs is a major factor
inﬂuencing the performance of a series of non-invasive
biomarkers. Moreover, APRI and Fibrotest-Fibrosure had
the best performance for the diagnosis of signiﬁcant
ﬁbrosis and cirrhosis in various aetiologies of CLDs. This
study represents one of the few and the largest in which
a direct comparison of the performance of non-invasive
biomarkers for liver ﬁbrosis in aetiologies other than
HCV has been carried out. Our study has also shown
that the performance of non-invasive biomarkers for
liver ﬁbrosis may be distinct in special subgroups of
patients who are expected to have a peculiar distribution
of ﬁbrosis stages, such as HCV carriers with normal
ALT and elderly HCV patients. Although these two
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subgroups of HCV patients are highly represented in the
general population and the indication to liver biopsy
remains controversial, few studies have speciﬁcally inves-
tigated the performance of non-invasive biomarkers in
them. Moreover, our study represents the ﬁrst large-
scale, multicentre, independent study that evaluated the
effect of the stages of hepatic ﬁbrosis on the performance
of the most validated non-invasive biomarkers for liver
ﬁbrosis. Indeed, it has been suggested that the prevalence
of liver ﬁbrosis stages may be a major factor of variabil-
ity in assessing the diagnostic value of a ﬁbrosis marker,
usually evaluated and compared using AUROC, and it
may be a cause of unsatisfactory results.23 According to
our results, the prevalence of liver ﬁbrosis stages may
have an effect on the AUROC, and should be taken into
account. Indeed, in our experience, the AUROC was
higher of 0.04–0.08 for all non-invasive biomarkers stud-
ied when corrected for DANA.
Staging of liver ﬁbrosis has been recognised as of par-
amount importance for both prognosis and management
of CLDs.3, 4, 36, 43 Liver biopsy has always been regarded
as the reference standard for liver ﬁbrosis assessment.10
However, it is invasive, costly and not feasible as screen-
ing tool for liver ﬁbrosis in CLDs, which affect millions
of people worldwide.11, 44 In recent years, many efforts
have been dedicated towards the identiﬁcation of non-
invasive tools for a more rapid, practical and less expen-
sive initial screening for disease stage and risk of pro-
gression. Several non-invasive biomarkers for liver
ﬁbrosis have been described, including simple methods
with virtually no cost, such as platelets, AAR, APRI, Fib-
4, Lok index and Forns’ index, and more elaborated pat-
ented panels of biomarkers, such as Fibrotest-Fibro-
sure.15–21 In clinical practice, the implementation of non-
invasive biomarkers for liver ﬁbrosis is still limited by
the scepticism shared by many clinicians on their perfor-
mance in substitution of liver histology, especially in
aetiologies other than CHC, where limited validation
exists.12, 13, 22, 45 Among the non-invasive biomarkers
investigated in our study, APRI and Fibrotest-Fibrosure
showed the best performance for diagnosis of signiﬁcant
ﬁbrosis and cirrhosis in all aetiologies of CLDs, even
when the AUROC was corrected for DANA. This ﬁnding
is coherent with other studies that compared the perfor-
mance of non-invasive biomarkers for liver ﬁbrosis.27, 46–49
Importantly, we showed that performance of APRI and
Fibrotest-Fibrosure may signiﬁcantly differ among vari-
ous aetiologies of CLDs. As regards APRI, it showed its
best performance in HCV monoinfected patients.
Although the performance was slightly inferior, no sig-
niﬁcant difference was observed in HIV ⁄HCV coinfected
cases. Moreover, we found a very high NPV (>97%) with
a cut-off value of 2 to exclude cirrhosis in both monoin-
fected and coinfected cases that could be useful in clini-
cal practice to select patients in whom the risk of having
cirrhosis is marginal. It has been suggested that perfor-
mance of APRI may be diminished in coinfected patients
because of HIV-related or antiretroviral-related thrombo-
cytopenia.50–52 Conversely, our results are in line with a
recent meta-analysis, which reported a tendency for
lower performance of APRI in HIV ⁄HCV coinfected
patients that did not reach the statistical signiﬁcance.51
On the same line, other studies reported a similar perfor-
mance of APRI in HIV ⁄HCV coinfected patients.53, 54 In
CHB, the performance of APRI was somehow unsatisfac-
tory for both signiﬁcant ﬁbrosis and cirrhosis, with an
AUROC always <0.70, even when corrected for DANA.
These results are in line with previous studies.27, 55 Only
one study reported a good performance of APRI for sig-
niﬁcant ﬁbrosis, as indicated by an AUROC of 0.86.56
The differences between the patient populations in this
study could be responsible for this disagreement. As
regards NASH, the performance of APRI was poor for
both signiﬁcant ﬁbrosis and cirrhosis, as indicated by an
AdjAUROC of 0.63 and 0.60 respectively. Similar results
have been reported in a small-scale study.57 Another
study investigated the performance of APRI for predic-
tion of cirrhosis in only 50 patients. The authors found a
discrete performance, as indicated by an AUROC of
0.786 for cirrhosis.58 Our results, based on 190 consecu-
tive patients, could not conﬁrm this initial report.
As regards Fibrotest-Fibrosure, it showed a good per-
formance in all aetiologies of CLDs, except for the diag-
nosis of signiﬁcant ﬁbrosis in NASH. Moreover, in all
aetiologies except for CHB, Fibrotest-Fibrosure showed a
very high NPV (>95%) to exclude presence of cirrhosis,
a result that could be useful in clinical practice to select
patients in whom the risk of having cirrhosis is marginal.
Similar to APRI, Fibrotest-Fibrosure showed its best per-
formance in HCV monoinfected cases. The performance
of Fibrotest-Fibrosure in patients with HIV ⁄HCV coin-
fection was similar to that found for monoinfected HCV
patients. One initial study of 130 HIV ⁄HCV coinfected
patients coming from the group that patented the test
reported an excellent AUROC of 0.856 for the prediction
of signiﬁcant ﬁbrosis.29 However, a following study of
272 patients, which took into account also DANA,
reported lower performances that were similar to our
results, as indicated by an ObAUROC of 0.64 for signiﬁ-
cant ﬁbrosis, that raised to 0.78 when corrected by
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DANA, and 0.81 for cirrhosis.52 The performance of Fi-
brotest-Fibrosure in CHB was investigated in few studies.
The reported AUROC ranged from 0.76 to 0.85 for diag-
nosis of signiﬁcant ﬁbrosis and from 0.76 to 0.80 for
diagnosis of cirrhosis that are somehow in line with the
results of the present study.27, 28 Interestingly, it has been
recently suggested that Fibrotest-Fibrosure may have a
role in the follow-up of HBV inactive carriers as well as
better selection of patients who require a liver
biopsy.33, 59 As regards NASH, very few reports investi-
gated the role of Fibrotest-Fibrosure.60 In our experience,
Fibrotest-Fibrosure had a high performance to diagnose
cirrhosis, with a very high NPV (>96%) to exclude cir-
rhosis and an overall AdjAUROC of 0.89. As, to our
knowledge, this is the ﬁrst independent application of Fi-
brotest-Fibrosure in NASH patients, this result deserves
attention and should be conﬁrmed by other studies. It
should be here underlined that Fibrotest-Fibrosure has
the advantage of classifying all the cases, while APRI
leaves up to 41% of cases unclassiﬁed.
Thanks to the large number of patients included in
our cohort, we were also able to perform a subgroup
analysis aimed at assessing the performance of non-inva-
sive biomarkers and the effect of DANA in patients who
may have a peculiar distribution of liver ﬁbrosis stages,
including HCV patients with normal ALT and HCV
elderly patients. In clinical practice, these groups of
patients are very frequent and may be the ones in whom
liver biopsy is even more questionable, and a reliable
non-invasive tool is highly needed.40, 42 Indeed, regard-
less of ALT levels, the decision to initiate anti-viral ther-
apy should be individualised based on the severity of
liver disease assessed by liver biopsy, the potential of
serious side effects, the likelihood of response and the
presence of comorbidities.40 Few studies have investi-
gated the role of non-invasive biomarkers in patients
with normal ALT.61–66 Some studies suggested that per-
formance of non-invasive biomarkers is in line with that
in patients with elevated ALT.61 Conversely, other
reports suggested that performance of non-invasive bio-
markers may be somewhat reduced in patients with nor-
mal ALT.62, 63, 65, 66 Our study, based on a large series
of cases in which the prevalence of signiﬁcant ﬁbrosis
was in line with previous population studies,14 indicates
that the performance of non-invasive biomarkers is
reduced in patients with normal ALT, even when AU-
ROC is adjusted according to ﬁbrosis stages distribution.
Consequently, the clinical use and interpretation of these
markers in this subgroup of patients should be cautious.
In elderly HCV patients, the greater prevalence of liver
disease is linked to higher morbidity and mortality,
which are excellent reasons for improving the evaluation
of liver ﬁbrosis and to better identify indication to anti-
viral therapies.41, 42 A single report by Poynard and col-
leagues investigated the role of Fibrotest-Fibrosure in
elderly patients with CHC, and a good performance of
the patented panel was reported.67 Interestingly, in our
study, platelets showed a very good performance to diag-
nose cirrhosis in this subgroup of patients. Indeed, a cut-
off of 150 000 ⁄mm3 had an excellent NPV to exclude
the presence of cirrhosis. A good performance of plate-
lets in excluding cirrhosis has been already reported, but
this is the ﬁrst study to assess its performance in a large
series of elderly HCV patients.68 This ﬁnding could be
useful in clinical practice as ﬁrst line approach through a
simple, inexpensive biomarker to select elderly patients
in whom the risk of having cirrhosis is trivial. Elderly
HCV patients are indeed more at risk of having
advanced ﬁbrosis, but the clinician is less prone to per-
form a liver biopsy in them as the procedure is likely to
be more risky than in younger patients.41 It has been
shown that complications related to liver biopsy proce-
dure are more severe in patients with underlying cardiac
or pulmonary disease, who also have a higher operative
risk than younger patients.69 As a consequence of the
fear of the physician towards liver biopsy, elderly
patients may be at risk of undermanagement, even
though they generally present with a more severe disease
and a faster ﬁbrosis progression.
The present study has several strengths. The use of a
multicentre cohort of well-characterised patients from
numerous centres across the world gave us the opportu-
nity to obtain a very large population of patients of dif-
ferent aetiologies, and with a wide spectrum of liver
disease, ranging from absence of ﬁbrosis to well-compen-
sated, subclinical cirrhosis. For many of the non-invasive
biomarkers investigated, this study represents one of the
few independent validations, particularly in aetiologies
other than CHC.
We acknowledge several limitations to our analysis.
Indeed, this is a retrospective study and potential selection
bias of patients may derive. The mean length of the liver
biopsy in this study was 17.7 mm, which is somehow sub-
optimal according to recently recommended threshold of
20 mm.10 However, we have investigated the effect of liver
biopsy size on the performance of non-invasive markers
and we found a similar performance for subjects with
biopsy samples of <20 mm as compared to those with
specimens >20 mm. This result is in line with other
reports, in which the length of liver biopsy did not
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inﬂuence signiﬁcantly the performance of the non-inva-
sive methods investigated.19, 70 Interestingly, according to
other recommendations, a biopsy specimen of 15 mm
length gives sufﬁcient histological information.71 No
information about fragmentation of liver biopsy speci-
mens was available in the present study. Indeed, it has
been demonstrated that the number of fragments may
have a signiﬁcant impact on the AUROC of non-invasive
markers.72 Our study did not have a central pathologist
for the interpretation of liver histology. Lack of evaluation
by a single Pathologist of all biopsies could be seen as a
weakness of our study, but it better describes what occurs
in real life. Moreover, the use of morphometric quantiﬁca-
tion of liver ﬁbrosis would have minimised subjectivity in
the assessment of hepatic ﬁbrosis.73, 74 It should be here
underlined that liver biopsy remains an imperfect gold
standard due to intraobserver and interobserver variabil-
ity, which mainly depends on the quality of liver speci-
men.75–78 Moreover, it has been shown that even in the
subpopulation with biopsy length ‡25 mm, there is still
35% of risk of false positive ⁄negative of the biopsy
result.76 Mehta and colleagues have recently suggested
that in the most favourable scenario, an AUROC >0.90
cannot be achieved when assessing signiﬁcant ﬁbrosis
even for a perfect markers and that a correct way to vali-
date non-invasive markers for liver ﬁbrosis vs. liver biopsy
would be to perform prospective studies using clinical
outcomes.79 Nevertheless, as liver biopsy remains the only
direct way to assess liver histology, guidelines still recom-
mend it for the staging of hepatic ﬁbrosis.3, 36, 43
In conclusion, this large-scale, independent study sug-
gests that the performance of non-invasive biomarkers
can be highly inﬂuenced by aetiology of CLD. The stages
of hepatic ﬁbrosis may also inﬂuence the performance as
expressed by AUROC, especially in subgroups of patients
where peculiar distribution of liver ﬁbrosis stages is
expected. Finally, among a series of non-invasive biomar-
kers, APRI and Fibrotest-Fibrosure showed the best per-
formance. Both these non-invasive biomarkers may be
used in clinical practice to safely exclude cirrhosis in
HCV monoinfected and HIV ⁄HCV coinfected cases. The
choice of the method may depend on the local availabil-
ity and experience of the clinician. APRI could be the
ﬁrst choice in regions with limited healthcare resources.
On the other hand, Fibrotest-Fibrosure has the advantage
to classify all cases, while APRI leaves a signiﬁcant per-
centage of cases unclassiﬁed. In patients with NASH,
Fibrotest-Fibrosure may also be applied in clinical prac-
tice to exclude cirrhosis, while it cannot be satisfactorily
used for the diagnosis of signiﬁcant ﬁbrosis. In elderly
HCV patients, presence of cirrhosis may be excluded
with high certainty with a speciﬁc cut-off of platelets. For
the diagnosis of signiﬁcant ﬁbrosis, especially in HCV
carriers with normal ALT, performance of non-invasive
biomarkers is not such to substitute liver biopsy. Further
prospective studies about application of the most promis-
ing non-invasive biomarkers for liver ﬁbrosis, especially
in aetiologies other than HCV and using clinical out-
comes as reference standard, are needed.
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